• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

反向工程路易体:我们已经走了多远,还能走多远?

Reverse engineering Lewy bodies: how far have we come and how far can we go?

机构信息

Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

ND BioSciences, Epalinges, Switzerland.

出版信息

Nat Rev Neurosci. 2021 Feb;22(2):111-131. doi: 10.1038/s41583-020-00416-6. Epub 2021 Jan 11.

DOI:10.1038/s41583-020-00416-6
PMID:33432241
Abstract

Lewy bodies (LBs) are α-synuclein (α-syn)-rich intracellular inclusions that are an important pathological hallmark of Parkinson disease and several other neurodegenerative diseases. Increasing evidence suggests that the aggregation of α-syn has a central role in LB formation and is one of the key processes that drive neurodegeneration and pathology progression in Parkinson disease. However, little is known about the mechanisms underlying the formation of LBs, their biochemical composition and ultrastructural properties, how they evolve and spread with disease progression, and their role in neurodegeneration. In this Review, we discuss current knowledge of α-syn pathology, including the biochemical, structural and morphological features of LBs observed in different brain regions. We also review the most used cellular and animal models of α-syn aggregation and pathology spreading in relation to the extent to which they reproduce key features of authentic LBs. Finally, we provide important insights into molecular and cellular determinants of LB formation and spreading, and highlight the critical need for more detailed and systematic characterization of α-syn pathology, at both the biochemical and structural levels. This would advance our understanding of Parkinson disease and other neurodegenerative diseases and allow the development of more-reliable disease models and novel effective therapeutic strategies.

摘要

路易体(Lewy bodies,LB)是富含α-突触核蛋白(α-synuclein,α-syn)的细胞内包涵体,是帕金森病和其他几种神经退行性疾病的重要病理学标志。越来越多的证据表明,α-syn 的聚集在 LB 形成中起核心作用,是驱动帕金森病神经退行性变和病理进展的关键过程之一。然而,对于 LB 的形成机制、其生化组成和超微结构特性、在疾病进展过程中如何演变和传播,以及它们在神经退行性变中的作用,人们知之甚少。在这篇综述中,我们讨论了目前对 α-syn 病理学的认识,包括不同脑区观察到的 LB 的生化、结构和形态特征。我们还回顾了最常用于研究 α-syn 聚集和病理传播的细胞和动物模型,以及它们在多大程度上再现了真实 LB 的关键特征。最后,我们深入探讨了 LB 形成和传播的分子和细胞决定因素,并强调了更详细和系统地表征 α-syn 病理学的迫切需要,包括生化和结构水平。这将有助于我们深入了解帕金森病和其他神经退行性疾病,并开发出更可靠的疾病模型和新的有效治疗策略。

相似文献

1
Reverse engineering Lewy bodies: how far have we come and how far can we go?反向工程路易体:我们已经走了多远,还能走多远?
Nat Rev Neurosci. 2021 Feb;22(2):111-131. doi: 10.1038/s41583-020-00416-6. Epub 2021 Jan 11.
2
The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.路易体的形成过程,而不仅仅是α-突触核蛋白的纤维化,是神经退行性变的主要驱动因素之一。
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4971-4982. doi: 10.1073/pnas.1913904117. Epub 2020 Feb 19.
3
Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.路易体是否含有α-突触核蛋白纤维?这有关系吗?对近期报告的简要历史回顾和批判性分析。
Neurobiol Dis. 2020 Jul;141:104876. doi: 10.1016/j.nbd.2020.104876. Epub 2020 Apr 25.
4
Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro.来自路易小体患者的α-突触核蛋白具有独特的病理活性,这种活性可以在体外传播。
Acta Neuropathol Commun. 2021 Nov 24;9(1):188. doi: 10.1186/s40478-021-01288-2.
5
Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.针对不同体外纤维形式的新型构象选择性 alpha 突触核蛋白抗体在帕金森病中显示出不同的路易体病理模式。
Neuropathol Appl Neurobiol. 2017 Dec;43(7):604-620. doi: 10.1111/nan.12402. Epub 2017 May 15.
6
Neuropathology of synuclein aggregates.突触核蛋白聚集体的神经病理学
J Neurosci Res. 2000 Jul 15;61(2):121-7. doi: 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4.
7
The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches.α-突触核蛋白在神经退行性疾病中的作用:从疾病的分子途径到治疗方法。
Curr Alzheimer Res. 2013 Jul;10(6):559-68. doi: 10.2174/1567205011310060002.
8
A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in Parkinson disease.一种光诱导的蛋白质聚集系统,用于帕金森病中α-突触核蛋白聚集的体内分析。
PLoS Biol. 2022 Mar 9;20(3):e3001578. doi: 10.1371/journal.pbio.3001578. eCollection 2022 Mar.
9
Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.A53T 转基因小鼠中特定区域的α-突触核蛋白寡聚物:对神经退行性变的影响。
J Neurosci. 2010 Mar 3;30(9):3409-18. doi: 10.1523/JNEUROSCI.4977-09.2010.
10
E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment.E46K 人类α-突触核蛋白转基因小鼠出现路易小体样和tau 病理学改变,伴有年龄依赖性、进行性运动障碍。
J Biol Chem. 2011 Oct 7;286(40):35104-18. doi: 10.1074/jbc.M111.247965. Epub 2011 Aug 16.

引用本文的文献

1
Parkinson's Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation.帕金森病:弥合差距、构建生物标志物及重塑临床转化
Cells. 2025 Jul 28;14(15):1161. doi: 10.3390/cells14151161.
2
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.路易体痴呆显性和前驱期生物学框架的意义与机遇
Alzheimers Dement. 2025 Jul;21(7):e70470. doi: 10.1002/alz.70470.
3
Combining light-induced aggregation and biotin proximity labeling implicates endolysosomal proteins in early α-synuclein oligomerization.

本文引用的文献

1
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.tau 分子多样性导致阿尔茨海默病的临床异质性。
Nat Med. 2020 Aug;26(8):1256-1263. doi: 10.1038/s41591-020-0938-9. Epub 2020 Jun 22.
2
α-Synuclein aggregation nucleates through liquid-liquid phase separation.α-突触核蛋白通过液-液相分离发生聚集。
Nat Chem. 2020 Aug;12(8):705-716. doi: 10.1038/s41557-020-0465-9. Epub 2020 Jun 8.
3
Pronounced α-Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala.
结合光诱导聚集和生物素邻近标记表明内溶酶体蛋白参与早期α-突触核蛋白寡聚化。
iScience. 2025 Jun 6;28(7):112823. doi: 10.1016/j.isci.2025.112823. eCollection 2025 Jul 18.
4
Probing the effect of the disordered flank regions on amyloid fibril growth and proliferation.探究无序侧翼区域对淀粉样纤维生长和增殖的影响。
RSC Adv. 2025 Jun 18;15(26):20668-20681. doi: 10.1039/d5ra01654a. eCollection 2025 Jun 16.
5
Multiplex Immunofluorescent Analysis of Alpha-Synuclein in Nigral Lewy Bodies With Heat-Induced Antibody Stripping Reveals an Intricate Multilayered Structure.采用热诱导抗体洗脱法对黑质路易小体中的α-突触核蛋白进行多重免疫荧光分析,揭示了一种复杂的多层结构。
Neuropathol Appl Neurobiol. 2025 Jun;51(3):e70024. doi: 10.1111/nan.70024.
6
Choroid plexus enlargement contributes to motor severity via regional glymphatic dysfunction in Parkinson's disease.脉络丛增大通过帕金森病中局部类淋巴系统功能障碍导致运动严重程度增加。
NPJ Parkinsons Dis. 2025 May 22;11(1):134. doi: 10.1038/s41531-025-00971-8.
7
Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.用于治疗α-突触核蛋白病的单克隆α-突触核蛋白抗体amlenetug(Lu AF82422)的合理选择。
NPJ Parkinsons Dis. 2025 May 22;11(1):132. doi: 10.1038/s41531-024-00849-1.
8
Criterion for Assessing Accumulated Neurotoxicity of Alpha-Synuclein Oligomers in Parkinson's Disease.评估帕金森病中α-突触核蛋白寡聚体累积神经毒性的标准。
Int J Numer Method Biomed Eng. 2025 Apr;41(4):e70027. doi: 10.1002/cnm.70027.
9
The role of Ergothioneine in cognition and age-related neurodegenerative disease: a systematic review.麦角硫因在认知及年龄相关性神经退行性疾病中的作用:一项系统综述。
Inflammopharmacology. 2025 Apr 18. doi: 10.1007/s10787-025-01746-6.
10
Serine-129 phosphorylated -synuclein drives mitochondrial dysfunction and calcium dysregulation in Parkinson's disease model.丝氨酸129磷酸化的α-突触核蛋白在帕金森病模型中导致线粒体功能障碍和钙调节异常。
Front Aging Neurosci. 2025 Mar 31;17:1538166. doi: 10.3389/fnagi.2025.1538166. eCollection 2025.
基于种子的小鼠模型中明显的α-突触核蛋白病理学不足以导致纹状体和杏仁核中线粒体呼吸缺陷。
eNeuro. 2020 Aug 17;7(4). doi: 10.1523/ENEURO.0110-20.2020. Print 2020 Jul/Aug.
4
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates.鉴定源自于患者α-突触核蛋白结构的不同病理特征在非人灵长类动物中的诱导作用。
Sci Adv. 2020 May 13;6(20):eaaz9165. doi: 10.1126/sciadv.aaz9165. eCollection 2020 May.
5
Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.路易体是否含有α-突触核蛋白纤维?这有关系吗?对近期报告的简要历史回顾和批判性分析。
Neurobiol Dis. 2020 Jul;141:104876. doi: 10.1016/j.nbd.2020.104876. Epub 2020 Apr 25.
6
Protein-Protein Interactions in Alpha-Synuclein Biogenesis: New Potential Targets in Parkinson's Disease.α-突触核蛋白生物合成中的蛋白质-蛋白质相互作用:帕金森病的新潜在靶点。
Front Aging Neurosci. 2020 Mar 17;12:72. doi: 10.3389/fnagi.2020.00072. eCollection 2020.
7
The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.路易体的形成过程,而不仅仅是α-突触核蛋白的纤维化,是神经退行性变的主要驱动因素之一。
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4971-4982. doi: 10.1073/pnas.1913904117. Epub 2020 Feb 19.
8
Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy.鉴别帕金森病和多系统萎缩中的α-突触核蛋白菌株。
Nature. 2020 Feb;578(7794):273-277. doi: 10.1038/s41586-020-1984-7. Epub 2020 Feb 5.
9
The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure.α-突触核蛋白遗传突变 E46K 解锁了一种更稳定、致病性的纤维结构。
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3592-3602. doi: 10.1073/pnas.1917914117. Epub 2020 Feb 3.
10
Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts.从患者脑组织提取物中放大的α-突触核蛋白纤维的结构异质性。
Nat Commun. 2019 Dec 4;10(1):5535. doi: 10.1038/s41467-019-13564-w.